title: Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study.
abstract: OBJECTIVE
  To evaluate the efficacy, safety, and tolerability of oxcarbazepine (1,200 mg/day) vs placebo as prophylactic therapy for patients with migraine headaches.
  
  
  METHODS
  This multicenter, double-blind, randomized, placebo-controlled, parallel-group trial consisted of a 4-week single-blind baseline phase and a 15-week double-blind phase consisting of a 6-week titration period, an 8-week maintenance period, and a 1-week down-titration period, after which patients could enter a 13-week open-label extension phase. During the 6-week titration period, oxcarbazepine was initiated at 150 mg/day and increased by 150 mg/day every 5 days to a maximum tolerated dose of 1,200 mg/day. The primary outcome measure was change from baseline in the number of migraine attacks during the last 28-day period of the double-blind phase.
  
  
  RESULTS
  Eighty-five patients were randomized to receive oxcarbazepine and 85 to receive placebo. There was no difference between the oxcarbazepine (-1.30) and placebo groups in mean change in number of migraine attacks from baseline during the last 28 days of double-blind phase (-1.74; p = 0.2274). Adverse events were reported for 68 oxcarbazepine-treated patients (80%) and 55 placebo-treated patients (65%). The majority of adverse events were mild or moderate in severity. The most common adverse events (>or=15% of patients) in the oxcarbazepine-treated group were fatigue (20.0%), dizziness (17.6%), and nausea (16.5%); no adverse event occurred in more than 15% of the placebo-treated patients.
  
  
  CONCLUSIONS
  Overall, oxcarbazepine was safe and well tolerated; however, oxcarbazepine did not show efficacy in the prophylactic treatment of migraine headaches.
authors.affiliation: Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA. Stephen.Silberstein@Jefferson.edu
authors.forename: S
authors.initials: S
authors.lastname: Silberstein
authors.forename: J
authors.initials: J
authors.lastname: Saper
authors.forename: F
authors.initials: F
authors.lastname: Berenson
authors.forename: M
authors.initials: M
authors.lastname: Somogyi
authors.forename: K
authors.initials: K
authors.lastname: McCague
authors.forename: J
authors.initials: J
authors.lastname: D'Souza
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage*; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004244:Dizziness / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D009325:Nausea / Q000139:chemically induced; D000078330:Oxcarbazepine; D010919:Placebos; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D010919:Placebos; D002220:Carbamazepine; D000078330:Oxcarbazepine